



the
abdus salam
international centre for theoretical physics

H4.SMR/1202-37


**"Fifth Course on Mathematical Ecology
including and introduction to Ecological Economics"**

28 February - 24 March 2000

REMARKS ON MODELING HOST-PATHOGEN SYSTEMS

Jorge X. Velasco-Hernández

Departamento de Matemáticas
UNAM-Iztapalapa
México D.F.
Mexico



Remarks on Modeling Host-Pathogen Systems

Jorge X. Velasco-Hernández
Departamento de Matemáticas
UAM Iztapalapa, México

José A. García
Departamento de Investigación
Universidad La Salle, México

Denise E. Kirschner
Department of Microbiology and Immunology
University of Michigan, USA

1 Introduction

Mathematical modeling of host-pathogen interactions is playing an increasingly important role in our understanding of the pathogenesis of infectious diseases. Many of the results have shaped our understanding of diseases processes both at the population and cellular level. In this chapter we give an introduction to modeling the interaction of the human immune system with viral and bacterial pathogens. Our collective research experience is focused on HIV so we use that as our prime example to explore approaches to understanding host-pathogen interactions and the treatment of disease. We present basic principles on the interaction of the immune system and the diverse set of pathogens that can attack the body. We then present a brief review of models for host-pathogen interactions at the cellular level, a summary of the modeling HIV disease progression and subsequent chemotherapy, and finally, we present a model for the treatment of AIDS using the novel approach of robust control theory.

2 Host-pathogen interactions

The immune response represents a complex defense system against invading pathogens. Its main features involve induction, specificity and memory. Most organisms possess a non-specific procedure for protection against pathogens: an innate response composed of physical and chemical barriers. Higher organisms also maintain an adaptive response comprised by humoral and cellular components that are pathogen specific (see [51]).

The most popular paradigm in immunology is that the key role of the immune response is to distinguish between self and non-self. This involves immune cells known as lymphocytes, that during their development, are suppressed if they recognize self [11]. Thus, immune cells that participate in the immune response recognize non-self molecules and can initiate the immune response cascade.

A second paradigm postulates that adaptive immune cells only respond if the antigen elicits different types and levels of tissue damage, not based on the nature of the antigen molecule [47], [70]. This model considers the immune response as a defense system against pathogens.

When both a foreign and harmful pathogen invades, an immune response is triggered. The innate elements attempt to suppress the invader, and only days later the specific immune component is developed. As the response progresses the pathogen attempts to survive by various evasion mechanisms. Thus, a series of complex interactions between the host and the parasite are established.

2.1 Immune response to bacteria

From the point of view of the parasite-host relationship, bacteria can be classified as either extracellular or intracellular. The former are eliminated when phagocytized by a professional phagocytic

cell such as neutrophils or macrophages. The later are able to survive and reproduce inside cells [10].

2.1.1 Extracellular bacteria

The main survival mechanism of these type of bacteria is to avoid or interfere with some aspect of phagocytosis. There is a considerable array of mechanisms that extracellular bacteria employ to evade being phagocytized. We offer two examples. First, some bacteria are able to assemble a polysaccharide capsule (e.g. *Streptococci*). As polysaccharides are weak antigens, the immune system fails to recognize it as foreign. As a consequence these bacteria are not "labeled" with molecules called opsonins (e.g. antibodies, complement fragments, acute phase proteins, etc.) that are required for receptor-mediated phagocytosis. Polysaccharides are so weak that the immune systems of infants and elderly individuals are not able to respond to them suffering dangerous infections (e.g. pneumonia).

Defense against these microorganisms depends on having appropriate antibodies to the capsular polysaccharide. Conjugate vaccines have been developed in which the polysaccharide has been covalently linked to a protein in order to enhance the cellular component of the immune response and to induce memory for future encounters.

Second, extracellular bacteria are able to secrete toxins that cause damage in tissues, one role of which is to distract the immune response. Here, usually an antibody specific for the toxin is enough to eliminate intoxication.

2.1.2 Intracellular bacteria

Intracellular bacteria are responsible for some of the most devastating diseases in human history: plague, leprosy, tuberculosis, typhoid fever, etc. The bacteria responsible in each case are able to survive within the macrophage. In some diseases the bacteria is eradicated, inconjunction with a delayed-type hypersensitivity (DTH) reaction induced in the host (as in tuberculosis). In other cases, the rate at which the bacteria is eliminated and its rate of reproduction are in equilibrium, so even if the infection is asymptomatic (without clinical manifestations), the individual sheds bacteria and can infect others (see [32]).

As the bacteria remains sheltered inside the macrophage, secreted antibodies are not able to reach the antigen. The main host defense mechanism in this case is the enhancement of the phagocytic abilities of macrophages which contain the intracellular bacteria. This is done through the helper action of a subclass of $CD4^+$ cell known as Th1 cells.

It has been demonstrated in mice that there exist two subpopulations of $CD4^+$ T cells, depending on the ensemble of cytokines that are produced (see [61]). Th1 lymphocytes secretes cytokines that favors the cellular immune response: Th1, macrophages, CTLs and NK (natural killer) cells are activated. On the other hand, the Th2 cells activate mainly B cells, so the humoral immune response is favored. In the case of a Th1 dominated response, the host usually suffers a less severe infection (e.g. individuals with Th1 response suffer tuberculoid lepra instead of lepromatous lepra which is more severe).

Infected cells can also signal the immune response via antigenic peptides presented in the context of MHC I, for recognition by specific cytotoxic T cells (CTLs) that kill the infected target cell. In either case the cellular immune response, controlled by Th1 cells, is responsible for the eradication of intracellular pathogens.

2.2 Modeling of Host-bacterial interactions

Relatively few models exploring bacteria-host level interactions have appeared [26], [35], [7], [9], [34], [27], [45], [46]. These models mainly focus on *M. tuberculosis*, mycoparasites, and the bacteria responsible for urinary tract infections. Each explores a key aspect of the host-pathogen interaction, such as the immune system response to introduction of the pathogen or chemotherapy of infection. These models are mostly based on differential equations due to the nature of the complex systems.

2.3 Immune response to virus

Unlike bacteria, viruses must infect host cells to survive and replicate. Once virus binds to the host nucleus the virus introduces its genetic material into the cell and resides there until it can replicate, eventually killing the host cell. This releases new virions which are able to infect other cells.

When the invading virus circulates through the blood its receptor could be blocked by neutralizing antibodies. However, once a virus has already infected a cell, specific antibodies can not reach it, and thus a cellular immune response is needed in order to suppress the infection.

Infected cells can be also recognized by natural killer cells and then killed through the action of perforin and other molecules secreted by the NK cell. Both CTLs and NK cells are activated by TH1 through the action of the cytokines interferon gamma ($\text{IFN-}\gamma$) and interleukin-2 (IL-2).

Perhaps the main immune evasion mechanism of viruses is mutation. As the body is preparing to fight the virus by developing specific responses, the virus changes some of its antigenic proteins via mutation, so it is no longer recognized. Retroviruses (like the human immunodeficiency virus) have a large spontaneous rate of mutation due to the enzyme called reverse transcriptase that does not possess a repair domain (exonuclease activity) which DNA polymerases usually have. This facilitates the mutation process.

2.4 Modeling Host-viral interactions

Models of viral infections, namely HIV-host models, have a successful recent history. Many of the key results that have shaped our understanding of the T-cell and viral dynamics in HIV disease have come from mathematical modeling approaches [31], [74], [66]. Many others have given insight into HIV-immune dynamics as well as progression [6], [5], [1], [58], [56], [57], [55], [48], [49], [37], [39], [42], [43], [41], [38], [4], [53], [54], [63], [6]. There is also a first attempt on modeling the interaction of cytokines and the HIV-infected immune system. This work examined the role of IL-2 immunotherapy in HIV-1 infection ([40]). Most of these models are continuous and deterministic, and thus have been formulated using ordinary or partial differential equations. A few of these models e.g. [53], [54] are discrete and stochastic. The choice of modeling method is based on several considerations; e.g., the time frame of a study, the population sizes, and the types of questions posed.

3 The Human immunodeficiency virus

HIV has been recognized as the etiologic agent of the acquired immunodeficiency syndrome -AIDS ([8]). The United Nations estimates that there have been 8.4 million AIDS cases since the start of the global pandemic in the 1980s, with an estimated 30 million persons HIV-positive. Only 1.5 million cumulative cases have been officially reported by countries. An estimated 5 million adults and 1.5 million children have already died from AIDS. The impact of this emerging infectious disease is clear. Despite the impressive amount of research on this pathogen and the related areas of study, there are as yet no effective vaccines or treatment strategies that prevent the ultimate progression to AIDS and death. This is sentinel in realizing that many of the pathogenic mechanisms leading to disease progression are still unknown.

HIV is a retrovirus containing two single strands of RNA. It is an enveloped virus that carries its own reverse transcriptase for transcribing the viral RNA. HIV is transmitted via three primary routes: sexually, vertically (mother to child) and intravenously. Once infection takes place, the interaction of HIV and the immune system begins with CD4^+ cells. The CD4 receptor appears mostly on helper T cells and some macrophages, and binds with the protein (ligand) gp120 (on the surface of the virus) initiating cellular infection. This is a necessary, but insufficient step – a co-receptor is also vital for proper cellular infection, and the virus uses a cytokine receptor on the surface of the host cell near the CD4 receptor to finish the lock-and-key entry process. It has been shown that those individuals lacking the co-receptor have a natural immunity to infection by HIV [23], although it is not known how this receptor mutation arose. It has been observed that initial infection with HIV usually occurs in macrophages, as the predominately-transmitted strain of HIV is tropic for the cytokine co-receptor on macrophages [71], [75]. These important phagocytes and

antigen presenting cells serve as a cloak for virus that can now be carried through the blood and lymph to all parts of the body (including crossing the blood-brain barrier). As infection progresses, HIV expands its co-receptor usage repertoire, and can infect both T cells and macrophages. There is much evidence to support the observation that this infection process occurs more efficiently in activated cells, and that even when a resting cell binds virus, the viral DNA may never be inserted into the host genome [60], [14].

Once inside, the viral DNA must be inserted into the host-cell's genome, and upon cellular activation, new viral particles are created and released. For HIV, viral production per infected cell is estimated to be on the order of 500 virions per infected cell [13], [29]. It has been observed that these infected cells (whether resting or active) are at an increased risk for cell death via apoptosis or other pathways [25]. This enhanced cell death is also seen in bystander cells (cells not producing HIV) [15]. Infected cells are also cleared via a CTL response, or may die due to lysis from infection.

As the infection develops, immune cells are depleted and a disruption in the immune system is established so that the host becomes susceptible to opportunistic infections and pathologies, like *Pneumocystis carinii* pneumonia (PCP), Kaposi's sarcoma, candidiasis, tuberculosis, etc. AIDS is diagnosed when the count in CD4⁺ T cells is less than 200/mm³ and/or the seropositive patient has one or more AIDS defining illnesses.

3.1 Modeling the Mechanisms of HIV Disease

Any theory or model of HIV disease progression needs to reconcile the following aspects of the disease process: (1) net loss of CD4⁺ lymphocytes is gradual and takes, on the average, 10 years; (2) CD4⁺ T cell numbers decrease in the blood earlier than in lymph nodes, and in the early symptomatic stages when CD4⁺ lymphocytes are declining in the blood, their numbers are often increasing in the lymph nodes (lymphadenopathy); (3) there is some compartmentalization of HIV-infected cells to lymphatic tissues with the preponderance of cells producing virus residing there, as well as most of the virus in the body being present on follicular dendritic cells; (4) the number of productively infected cells at any given time is very low, with approximately 10⁷ productively infected cells present in the whole body out of a total of 10¹² lymphocytes (1:10⁵ ratio); and (5) CD4⁺ lymphocytes that die, tend to die in lymph nodes, not in the peripheral blood, and those that are dying are mostly bystander cells. The factors determining the dynamics of the T cell populations during HIV infection can be classified into 3 main areas: a change in cell productions, a change in cell migration patterns, and a change in cell life-spans (i.e. increased cell death). Each of these dynamics is modulated by cytokines as well as other influences. Two hallmarks of immunopathogenesis in the progression of HIV to AIDS are the loss of CD4⁺ T cell function in response to antigens and the critical reduction of CD4⁺ T cell numbers. It is probable that these two phenomena are related. Other data point to a reduction in CD8⁺ T cell anti-HIV activity associated with disease progression.

3.1.1 HIV-1 Disease Progression

As mentioned above, models of HIV-immune dynamics have gained much attention since the mid 1980s. The first three works done in this area were by Cooper [20], Dolezal and Hraba [22] and Perelson [64]. For a recent review of HIV-immune models, see [65], [21]. The Perelson et al [63] model included populations of uninfected CD4⁺ T cells, latently infected CD4⁺ T cells, actively infected CD4⁺ T cells, and free HIV virus. This model provided a reasonable first approximation to the clinical progression of the disease, although the T-cell populations never declined to very low levels. This model was modified to include macrophages as a possible site of virus replication [38]; the result was a slower disease progression and a lower T-cell count, but the collapse of immunity (the "crash to AIDS") was always very abrupt. With both of these models chemotherapy was explored using a reverse transcriptase inhibitor, which was assumed to reduce viral production.

To improve the mechanistic basis for HIV models, we included anatomical compartments other than the peripheral blood compartment in which viral loads and T-cell counts are typically measured [37]. A compartment for the lymph system is included because there is evidence that lymph nodes become saturated early with infected T-cells and these provide a constant supply of virus to the

peripheral blood compartment throughout the infection [29], [44]. These preliminary results have given the most accurate simulations yet of the disease progression - including the slow decrease in CD4⁺ T cells, the quasi-constant viral load in peripheral blood until very late in the progression, and the long delay to the onset of AIDS [42].

3.1.2 Progression Models of HIV

Any model of HIV disease progression should incorporate clinically determined dynamic information about the HIV-infected immune system. The essential elements are as follows. After an initial period of acute viremia in the first few weeks after seroconversion, CD4⁺ T-cell counts decline gradually from approximately 600 to 800/mm³ to almost 0/mm³ over approximately 10 years (normal CD4⁺ T-cell counts are 800 to 1,200/mm³). Data from [62] is shown in Figure 1. The decline of CD4⁺ T cells is more rapid early in the infection [67]. Infected CD4⁺ T cells constitute 4% or less of the CD4⁺ T-cell population [24]. The half-life of an infected CD4⁺ T cell is approximately 2 days [31], [74], [66], [16]. After the initial viremia, plasma virus increases from below 10⁴/ml to 10⁷/ml or more during the variable course of infection with a sharper increase toward the end of the symptomatic phase [62]. The lifespan of a virus outside the cell is about 7.2 hrs [31], [74], [66].

Figure 1




Figure 1: Data from [62] averaged from untreated patient's CD4⁺ T cell counts and viral loads.

To model the longest stage of HIV infection, the asymptomatic phase, we developed a model [43], [42] consisting of ordinary differential equations for the variables $T(t)$ (the CD4⁺ T-cell population uninfected by virus at time t), $T^s(t)$ (the CD4⁺ T-cell population infected by drug-sensitive virus (wild-type) at time t), $T^r(t)$ (the CD4⁺ T-cell population infected by drug-resistant virus (mutant) at time t), $V_s(t)$ (the drug-sensitive virus population at time t), and $V_r(t)$ (the drug-resistant virus population at time t). All these virus populations reside in the circulating blood, in which the values of uninfected CD4⁺ T cells and virus can be clinically measured. The equations are presented below.

$$\frac{dT(t)}{dt} = s(t) + p(t)T(t) - \mu_T T(t) - \mathbf{P}_1 k_s T(t) V_s(t) - k_r T(t) V_r(t), \quad (1)$$

$$\frac{dT^s(t)}{dt} = k_s T(t) V_s(t) - \mu_{T_i^s} T^s(t) - p_i^s(t) T^s(t), \quad (2)$$

$$\frac{dT^r(t)}{dt} = k_r T(t) V_r(t) - \mu_{T_i^r} T^r(t) - p_i^r(t) T^r(t), \quad (3)$$




Figure 2: Model of HIV-immune system dynamics. The uninfected CD4⁺ T cell population has a source rate of s , and a death rate of μ . Cells are infected by either wild-type or resistant mutant virus, at rate k . These infected cells can produce either wild-type or mutant viral strains (which is dependent on the presence of drug for biased selection at rates q and p). Both infected cells and virus are cleared by immune response and death. There is an external source of virus (both types) from the lymph system (reprinted from [39]).

$$\frac{dV_s(t)}{dt} = q \cdot p_n^s(t)T^s(t) + (1 - q) \cdot p_n^r(t)T^r(t) - k_T(t)V_s(t) + P_2g_s(t), \quad (4)$$

$$\frac{dV_r(t)}{dt} = q \cdot p_n^r(t)T^r(t) + (1 - q) \cdot p_n^s(t)T^s(t) - k_T(t)V_r(t) + g_r(t). \quad (5)$$

Initial conditions are $T(0) = T_0$, $T^s(0) = 0$, $T^r(0) = 0$, $V_s(0) = V_{s0}$, $V_r(0) = 0$. If we assume that $k_s = k_r$ and sum the two equations for infected T cells ($T^i = T^r + T^s$) and similarly sum the viral equations ($V = V_s + V_r$), the equations reduce to that of the non-resistance model in [33],[43], [42].

The model is explained as follows. The terms of eq. 1, $s(t) + p(t)T(t)$, represent the source of new T cells. This incorporates T cells from the bone marrow, thymus and general production. It also includes proliferative production (whether direct or indirect) due to the presence of antigen. This production changes over the course of infection, which is accounted for in the time-dependent rates. This is followed by a natural death term, because cells have a finite life span; the average of which is $\frac{1}{\mu_T}$. The last two terms represent the infection of CD4⁺ T cells by both resistant and sensitive strains of virus. These terms are mass-action type terms with constant rates of infectivity k_s, k_r . We assume the law of mass action applies here based on the large numbers of cells and virion involved. P_1 represents the effects of treatment on viral infectivity in the plasma. Equations 2 and 3 describe changes in the infected population of CD4⁺ T cells, T^s and T^r , respectively. (We assume that, each T cell is dominated by, and hence producing, only one strain of the virus, either V_s or V_r .) The first gain terms for each carries over from the loss terms in eq. 1. Then, infected cells are lost by such processes as natural death, viral killing, apoptosis or homing to LS.

In equations 4 and 5, the first terms are the source for the virus population. Newly produced virion come from production by infected CD4⁺ T cells (from Eqs. 2 and 3), in which new virion are produced at rates $p_n^s(t)$ and $p_n^r(t)$, respectively. We assume that upon each replication there is a probability of $(1 - q)$ that a significant mutation will take place; and, that the proportion q remain faithful to the original strain.

As there is much evidence to support the major production of virus taking place in the lymphoid system (LS), we account for this phenomenon as a major contributor of virions, other than the small amount produced in the blood [44]. The input rates of lymphoid system virus are $g_s(t)$ and $g_r(t)$, for the sensitive and resistant viral strains, respectively. They are time dependent, as this will vary

over the course of infection. P_2 represents the effects of treatment on viral infectivity in the LS. The model (1)-(5) describes the interaction of the immune system with HIV.

A typical untreated disease course based upon $CD4^+$ T-cell counts and viral load is simulated from the model in Figure 3. The initial virus level is determined by the model's parameters. This assumption is consistent with recent clinical findings that disease prognosis is correlated to a set-point of virus level established in each patient soon after the initial viremia, and viral levels and replication rates remain relatively stable after the set-point [69], [12], [30], [52]. In the model, different set-points are obtained by varying key parameter values, such as viral burst size. This system is the only model to date that accurately captures clinic data [42]. This is now corroborated in published work from the Swiss HIV cohort study, where our model is used and gives consistent simulation of the clinical data during the long-term infection with HIV-1 [19].

Figure 2




Figure 3: A simulation of HIV dynamics for the model with initial T cell count at $1000 /\text{mm}^3$ and initial viral load at $10^4 /\text{ml}$. The curves correspond to data as shown in Figure 1. The set-point of the virus is in the middle range [30] and corresponds to a typical disease progression of about 6 years in this simulation.

3.2 Antiretroviral Therapy of HIV Infection

Clearly, there is a necessity for both prevention and treatment of HIV infection. There are no vaccines as yet available, but there are several drugs now employed to lower viral loads and raise $CD4^+$ T cell counts. These antivirals fall into two main categories: inhibitors of reverse transcriptase and inhibitors of protease. The role of reverse transcriptase inhibitors is to interfere with the transcription of the RNA to DNA thus, halting cellular infection; the role of protease inhibitors is to interfere with post-translational viral particle assembly. Unfortunately, these drugs are not cures for the infection, but only serve as maintenance programs to temporarily prevent further progress of the virus. Despite this drawback, there is much clinical evidence to support the use of combinations of these chemotherapies in HIV infected individuals. Aside from the possibility of prolonging life in an HIV positive individual, it may make them less infectious to their sexual partners [3], as well as reduce rates of mother to fetus transmission [59]. Controversy exists among clinicians, however, as to whom should be treated, when they should be treated, what treatment scheme should be used, and if it fails, what should be done in replacement therapy.

HAART (highly active antiretroviral therapy) is a cocktail of different antiretroviral drugs. The effectiveness of HAART in terms of slowing progression to AIDS is high for a large percentage of cases although it presents several problems in terms of drug resistance and compliance.

Most chemotherapies reduce viral production in a dose dependent manner but to the expense of multiple side effects, as well as ineffectiveness of the treatment after a certain time due to the

capability of the virus to mutate and become resistant to treatment [36].

3.2.1 Treatment Models

Mathematical models provide a means to understand the human immunodeficiency virus (HIV)-infected immune system as a dynamic process. Models formulated as differential equations for the dynamic interactions of CD4⁺ lymphocytes and virus populations are useful in identifying essential characteristics of HIV pathogenesis and chemotherapy. Recent clinical studies have produced new insight into the dynamics of these virus populations during HIV infection [31], [74], [66]. Turnover rates and lifespans of infected CD4⁺ T cells and virus have been identified by measuring their rates of change in patients undergoing strong antiviral monotherapy. The determination of these rates showed that large numbers of CD4⁺ T cells and virus are gained and lost each day throughout the course of HIV infection [31], [74], [66]; these findings have profoundly influenced strategies for therapy [16]. It is now recognized that chemotherapeutic agents must strongly suppress viral production before rapidly appearing viral mutants evolve to drug resistance. Recent clinical trials have had some success in using combined drug therapy [68], [69]. Ongoing trials with combinations of drugs have shown sharp declines of viral counts to undetectable levels within several weeks of treatment; these levels are sustained for 1 year or more [69], [72], [12]. At the same time, CD4⁺ T-cell counts rise markedly before gradually leveling off [69], [72], [12]. This apparent remission of HIV infection offers hope for potential chronic control [16]. The long-term implications of patients on this therapy, however, are not yet fully understood.

3.2.2 Relevance of HIV-1 Progression Models to Treatment and Resistance

In the absence of any chemotherapy, it can be assumed that the sensitive strain of virus is dominant; but in the presence of treatment, selection is for resistant strains. Because of the development of resistance and side effects during single drug chemotherapy, the time frame for which the drug can be administered is finite and usually less than two years [50], [73]. This phenomenon can be modelled by treating for a 52 week window during the course of infection. Simulations of viral dynamics can be made using the total CD4⁺ T cell population over time together with HIV levels as indicators of drug effectiveness. To include monotherapy in the model, it is necessary to mathematically mimic the effects of a drug which is a reverse transcriptase inhibitor. Such drugs reduce viral infectivity, since they do not allow the viral DNA to be inserted into the host genome. Since multiple virions may infect a cell, such drugs may inhibit one virus, but allow another to get through or around the drug barrier. One can therefore model treatment by inhibiting the infectivity of the virus. This would affect both the viral infectivity of T cells, and also reduce the number of infectious virus flowing into the blood from the LS virus compartment. One can achieve this by multiplying the parameters k_s and g_s in the model by functions which are "off" outside the treatment period (thus having no effect) and "on" during the treatment period (thus reducing viral infectivity). Treatment functions which achieve this are of a piecewise continuous form with the values outside the treatment period, and P_1 within the treatment period. P_1 is the treatment effectiveness, $0 < P_1 < 1$. If $P_1 = 1$, there is no treatment effectiveness; if $P_1 = 0$, there is no viral production. A similar function, with treatment parameter P_2 , is also applied to the external LS, however with less effect (i.e. $P_1 < P_2$, since it is proportionate reduction) as we assume the drug effectiveness is less there [44]. Drugs such as AZT reduce viral activity in a dose dependent manner. The efficacy of the chemotherapy may differ from patient to patient; therefore, P_i for $i \in \{1, 2\}$ represents the varying effectiveness of the drug in halting viral activity in a given patient.

Certain models of treatment (e.g. [43], [42]) distinguish qualitatively two outcomes indicated by clinical trials. The first is resistance. Examples of resistance for three-drug combined therapy are reported for completed clinical trials by Collier et al. [18]. In these trials, there was on average an increase of CD4⁺ T-cell counts by approximately 30% (peaking at approximately 8 weeks and returning to baseline at approximately 40 weeks) and a decrease of plasma virus by approximately 70% (peaking at approximately 4 weeks and recovering to half baseline at approximately 40 weeks). The second treatment outcome is *remission*. Examples of remission are indicated in preliminary reports of ongoing clinical trials [69], [12], [60], [17]. In these trials, two things were observed 1)

plasma virus decreased sharply to nondetectable levels in 2 to 4 weeks, and these levels are sustained for periods of 1 year or more, and 2) $CD4^+$ T-cell counts increased steadily by $100/\text{mm}^3$ or more before gradually leveling off to below normal levels (this below normal recovery is believed to be due to an impaired production of new $CD4^+$ T cells from the thymus and other sources [62], [28]; this assumption is incorporated into the model).

Multi-drug treatment can be incorporated into the existing model as the reduction of two separate rates. The reduction of these rates provides treatment control variables corresponding to the intensity and velocity of HAART drug action. The variables are the rate at which virus infects uninfected $CD4^+$ T cells and the rate of virus influx into the plasma from the lymph system. Reduction of this second rate is the most important for treatment outcome, since it is believed that as much as 98% of the virus in the circulating blood is contributed by the external lymphoid compartment [69], [12]. In the simulations, the dynamics in the lymphoid compartment are modeled as a viral source term rather than mechanistically, since limited data are available for the host-pathogen dynamics in this compartment [44], [29]. When treatment begins, the model assumes that a proportion of drug-sensitive virus mutates to drug-resistant virus. This proportion is also a treatment control variable corresponding to the combination of drugs used or the presence of genetic diversity at different disease stages [49].

The model distinguishes primarily between resistance and remission in the assumption of a threshold condition for the virus population in the plasma (and thus for the virus population in the lymphoid compartment). The threshold condition is incorporated into the rate that controls the contribution of drug-resistant virus from the external lymphoid compartment to the plasma. When treatment drives the plasma virus level below the threshold, the drug-resistant virus population does not emerge, and the drug-sensitive virus population falls to undetectable levels. This threshold cannot be reached simply by gradually lowering the drug-sensitive virus population. Two additional factors must be considered: 1) when the virus population is above threshold, the high mutational capacity and short lifespan of the virus results in rapid production of drug-resistant variants; and 2) as the virus population approaches the threshold, Darwinian competition gives competitive advantage to the resistant viral strain as the sensitive viral strain diminishes in fitness and in numbers.

To reach the threshold, the virus population must be brought down extremely fast before mutation and selection pressure allow resistant virus to propagate in the drug-altered environment. In the simulations, this rapid fall to the threshold can be achieved if treatment inhibits the rate of viral influx from the external lymphoid compartment term sufficiently fast. The threshold value depends on the drugs used and the capacity of the virus to mutate against these drugs. In some patients, plasma levels were reduced to undetectable levels, yet remission did not occur [31], [74]. In these cases, there may have been an extremely low threshold specific to the drugs used or a disproportionately lower suppression of virus in the lymphoid compartment than in the plasma.

Although computer models of HIV therapy are no substitute for clinical trials, they can bring into focus essential elements of the dynamic processes involved. The treatment simulations presented here identify the following qualitative dynamic elements involved in resistance and remission: 1) remission can occur if the viral production in the lymphoid tissues is suppressed below a threshold level; 2) drug action must be strong enough and fast enough to drive the virus population to the threshold before resistant virus appears and propagates; 3) combination therapy or early treatment lowers the capacity of the virus to mutate to resistant strains and thus forestalls their emergence until the threshold is reached. In the next section we present an approach to the modeling of chemotherapy in HIV.

4 A chemotherapy feedback control model

The question of whether or not treatment should be given in a constant or dynamic way remains open. Some scientists believe that it is too difficult to tailor a specific treatment regime for each individual patient. Others believe that in life-threatening diseases such as HIV, we should treat each patient with all available options. To this end, Kirschner et al [36] used optimal control methods to explore the issue of a dynamic treatment regime. They addressed this problem concentrating on




Figure 4: Treatment simulations for four starting viral levels. The simulations have a common viral set-point of disease progression, and the treatment starting values are from Figure 3. Initiation of treatment with the lowest starting viral load achieves remission (a), while the other three develop immediate resistance (reprinted from [42]).

when and how treatment should be initiated for patients who are in the early stages of infection where uninfected cell counts are high. Their optimal control approach has an objective function based on benefit, measured as the number of uninfected cell counts less the systemic cost of chemotherapy. Using a previously studied simple model of HIV-T cell dynamics ([63] given in (6-9) below), the authors concluded that a dynamically scheduled treatment protocol can maintain the uninfected cell counts in normal levels while reducing the side effects of chemotherapy.

Optimal control based solutions lack robustness against modeling errors and imperfect measurements, and depend strongly on the model used to compute the treatment scheduling. Host HIV dynamics are poorly understood. Therefore, misconstrued model dynamics and uncertainty in parameters may lead to faulty conclusions, such as failure of treatment due to unnecessary high doses or high virus counts due to low doses. We now present a different approach to HIV chemotherapy modeling using robust control summarizing the results of [2].

An alternative to optimal control strategies is the method of feedback control in which these problematic issues are routinely considered. The aim of this section is to summarize recent results that explore the use of robust control theory to design treatment scheduling for the treatment of HIV infected patients. Alvarez-Ramirez et al [2] considers the percentage effect of the chemotherapy on viral production as the target variable seeking to regulate the viral production via a feedback function where the percent of effect of chemotherapy is computed from actual measurements of viral and cells counts.

4.1 The HIV-immune system model

To illustrate the possibilities of the application of feedback control, the authors in [2] make use of the same mathematical model for HIV dynamics from Perelson et al [63] (given in (6-9) below), which was later used for the optimal control strategies applied to treatment as described above.

In the model, T denotes the concentration uninfected $CD4^+$ T cells, T_1 and T_2 denote respectively the concentration of latently infected (cells that contains virus but do not release them) and actively infected $CD4^+$ T cells (virus releasing cells). The concentration of free infectious virus particles is V . Definition and numerical information for the parameters can be found in Table 11 of Kirschner et al. [36].

$$\frac{dT(t)}{dt} = \frac{s}{1+V(t)} + rT(t)(1-f) - \mu_T T(t) - k_1 T(t)V(t), \quad (6)$$

$$\frac{dT_1}{dt} = k_1 T(t)V(t) - \mu_T T_1(t) - k_2 T_1(t), \quad (7)$$

$$\frac{dT_2}{dt} = k_2 T_1(t) - \mu_b T_2(t), \quad (8)$$

$$\frac{dV}{dt} = N\mu_b T_2(t) - k_1 V(t)T(t) - \mu_V V(t), \quad (9)$$

where $f = (T + T_1 + T_2)/T_{\max}$.

The model is briefly explained as follows (for a more complete description see [63]). The first term of Equation (6) represents the source of new CD4⁺ T cells from the thymus. This is followed by a natural death term. The next term represents the stimulation of CD4⁺ T to proliferate in the presence of virus. The last term represents the infection of CD4⁺ T cells by virus and is determined by the rate of encounters of CD4⁺ T cells with virus. Notice that the law of mass action was used here. In Equation (7), latently infected CD4⁺ T cells are assumed to have the same death rate μ_T as uninfected T cells, although other factors can augment their death rate [36]. Equation (8) models the actively infected CD4⁺ T cells. The first term represents the rate at which latently infected cells become actively infected cells. Actively infected cells produce virus and die at per capita rate μ_b . Equation (9) models the free virus population. The model assumes that when an actively CD4⁺ T cell becomes activated through exposure to antigen, replication of the virus is initiated and N viruses are produced before the host cell dies. The term $-\mu_V V$ accounts for viral loss of ineffectively and/or removal from the body. In the absence of virus, the T cell population has a unique steady state known as uninfected steady state such that $T_0 > 0$. Reasonable initial conditions for the differential equations system are $T(0) = T_0$, $T_1(0) = T_1^0$, $T_2(0) = T_2^0$ and $V(0) = V_0$. In particular, if the initial inoculum is free virus and not infected cells, then $T_1(0) = T_2(0) = 0$.

The system (6)-(9) has a second steady state [63]. The uninfected steady state represents a healthy individual, while the second steady state corresponds to a successful invasion of HIV (infected steady state), in which uninfected T cells have low positive concentration. It has been shown in [63] that if the parameter N is below a critical value N_c , the uninfected steady state is stable and the infected steady state is unstable. At $N = N_c$ a transcritical bifurcation occurs. If $N < N_c$, the uninfected steady state is globally asymptotically stable. Model (6)-(9) can be used to study the effects of chemotherapy [36], [63] by representing the effect of drug treatment as a reduction of the viral production rate as shown in [36]. Obviously, if chemotherapy reduces the number of virus production below the value N , then the immune system could recover and lead to the uninfected steady state. Thus, a treatment scheduling design is required to avoid proliferation of free infectious virus particles.

4.2 The Feedback treatment model

The control variable represents the percentage of effect the chemotherapy has on viral production. The authors in [2], [36], [63] mimic the effects of HAART, by assuming that chemotherapy reduces viral load; thus in Equation (9), the control $u(t)$ multiplies the number of free virus produced by $T_2(t)$ cells:

$$\frac{dV(t)}{dt} = u(t)N\mu_b T_2(t) - k_1 V(t)T(t) - \mu_V V(t). \quad (10)$$

We require the control to satisfy the restriction $0 \leq u(t) \leq 1$ where $u(t) = 1$ is the maximal use of chemotherapy. For design purposes, it is assumed that $N > N_c$, so the model does not evolve in the region of stability of the uninfected state (i.e. the individual has active HIV infection). Kirschner et al [36] defined a control objective functional that maximizes chemotherapy benefits based on the uninfected T cell counts. Alvarez-Ramirez et al [2] use a different control objective: the regulation of the free infectious virus particles about a low reference value by scheduling the chemotherapy dosage. This follows since a reduction of free infectious virus leads to a reduction of (latently and active) infected cells and, consequently, to an increase in uninfected cells. A feature of this approach is that the virus reference value is a design variable that can be prescribed in terms of the degree of infection and patient characteristics. As pointed out in [36], public health policies are being designed

to determine the time and degree of infection of each particular case and therefore health officials may want to treat under asymptomatic or symptomatic infection scenarios depending on viral load.

If V_r denotes the virus reference value, then it is assumed that the dynamic behavior of the free infectious virus particles is:

$$\frac{dV}{dt} = -\tau_c^{-1}(V(t) - V_r), \quad (11)$$

where $\tau_c > 0$ is a closed loop time constant. Notice that the dynamics of the above equation are asymptotically stable around the reference value V_r with τ_c as the convergence time. The feedback control law is based on a matching scheme. Provided $N\mu_b T_2 \neq 0$ for all positive t , exact model matching between (10) and (11) is achieved by the following feedback function:

$$u(t) = (k_1 V(t)T(t) + \mu_V V(t) - \frac{dV(t)}{dt}) / N\mu_b T_2(t). \quad (12)$$

The above function corresponds to feedback treatment since it is a function of the actual values of actively infected cell concentration $T_2(t)$ and of free infectious virus particles $V(t)$. Under the above control (12), the controlled dynamics are given by system (6-8) plus equation (11):

It can be proved that feedback control $u(t)$ given above can regulate the immune system-HIV dynamics to either steady state.

A major drawback of the feedback control function (12) is that perfect knowledge of the parameters and dynamics are required for its implementation. It is in this sense that the feedback function (12) is called *ideal scheduling treatment*. The model above is only an approximation of the real immune system-HIV dynamics and in fact, it does not account for some key aspects of the dynamics. In particular, parameter estimation from actual clinical data parameters is inexact as well as time varying, and even some model parameters are unobtained from clinical data. For instance, only rough estimates of the number of free virus produced by $T_2(t)$ cells are presently available. As in the case of optimal control based approaches [36], the design of treatment scheduling under these uncertainties may lead to undesired results (e.g. premature ineffectiveness of treatment due to unnecessary high doses or high virus counts due to low doses). The aim of this section is to use control theory tools to design a robust treatment scheduling in the face of model uncertainties.

The following assumptions are made for control design purposes:

- Free infectious virus particles and actively infected cell concentrations are available from (periodic) measurements. This is a reasonable assumption, since cell and virus counts can be obtained with present clinical techniques.
- Estimates of N , μ_b , μ_V are known denoted by \hat{N} , $\hat{\mu}_b$, $\hat{\mu}_V$ respectively. Clinical data are becoming more accessible, making it possible to get typical estimates of them [33].

We write the viral dynamics, $V(t)$, as

$$V'(t) = -\mu_V V(t) + \eta(V(t), T_2(t), u(t)) + \hat{\beta}u(t),$$

where $\hat{\beta} = \hat{N}\hat{\mu}_b$ and

$$\eta(V(t), T_2(t), u(t)) = -(\mu_V - \hat{\mu}_V)V(t) - k_1 V(t)T(t) + (N\mu_b - \hat{\beta})T_2(t)u(t)$$

is the model error function. The aim is to estimate $\eta(V(t), T_2(t), u(t))$ and to design a feedback function to approximate the optimal scheduling treatment function (12).

To estimate the model error $\eta(t)$, we introduce the observer

$$\hat{\eta}'(t) = \omega_e(\eta(t) - \hat{\eta}(t)),$$

where $\hat{\eta}(t)$ is the estimate of $\eta(t)$ and $\omega_e > 0$ is the estimation frequency, which is an adjustable parameter. If $e = \eta - \hat{\eta}$ is the estimation error then $e' = -\omega_e e + \eta'$. If the model error dynamics are bounded the idea is to pick a sufficiently large estimation frequency value and push the estimate modeling error towards the real modeling error. The implementation of this idea can be consulted in [2]. We now proceed to some numerical examples.

4.2.1 Numerical Simulations

In this section we study the controlled immune system HIV dynamics numerically to illustrate our treatment scheduling design as well as to provide evidence that our feedback control design is likely to work in more general situations. We assumed the following scenarios:

- Free virus and actively infected cell concentrations are measured every P days. Moreover, such measurement is delayed P days. This means that the sample for measurement is taken every P days and the actual measurement is available at the next sampling instant.
- An upperbound for the parameter N is $\hat{N} = 1800$ virus counts/cell [63]. Note that the estimated value $\hat{N} = 1800$ virus counts/cell has about 80% error with respect to the real value.
- We use the estimate $\hat{\mu}_b = 0.3/d$, such that the death rate of the $T_2(t)$ cell population is overestimated about 25%.
- Chemotherapy begins D days after the onset of infection. The estimated parameter becomes $\hat{\beta} = 240$ virion counts $\text{cell}^{-1}\text{d}^{-1}$.

Initial conditions are: $T(0) = 1000$ cells mm^{-3} , $T_1(0) = T_2(0) = 0$ cell mm^{-3} , and $V(0) = 0.001$ particles mm^{-3} . The control parameters are: $\tau_c = 7$ and $\omega_e = 0.05 \text{ d}^{-1}$; therefore, the desired reference value can ideally be achieved in about a week, and the cutoff period of the modeling error estimation about two weeks. Thus, system parameter changes can be detected in at most two weeks.

For comparison purposes the dynamical behavior of the uninfected cells and virus populations in absence of treatment are presented in Figure 5. Notice that for this set of parameters, the stage where uninfected cell concentration decreases rapidly starts 2–2.5 years after the onset of infection. In the first year, the virus and infected cell concentration are very small. This can be a drawback for treatment scheduling based on feedback control because the modeling error estimator may be insensitive to excessively small values of virus concentrations. Based on the numerical simulation displayed in Figure 5, we propose to use our feedback control scheme for treatment scheduling about 400 days after the onset of infection.




Figure 5: Time series plot of the solution to the model in equations (6-9) showing the virus and uninfected T cell populations.

Let the reference $V_r = 0.05$ particles mm^{-3} , corresponding to a steady state with about a 10% decrease in the normal uninfected T cell population. Figure 6 presents the dynamics of the immune

system-HIV interactions under chemotherapy computed from the proposed feedback control for three different values of the sampling period P ; namely, 7, 15 and 30 days, and $D = 1000$, corresponding to the beginning of the catastrophic stage of fast, uninfected T cell decrease. Examining the results, two things are evident. First, the reference value V_r is achieved in about 250 days. After this time, the treatment achieves a stationary value. Second, the smaller the sampling period, the better the performance of the chemotherapy administration. This point highlights the importance of monitoring frequently the evolution of T cell populations in HIV infected patients.




Figure 6: Dynamics of the immune-HIV interaction for different reference values of the sampling period, P at 7, 15 and 30 days.

Figure 7 presents results when varying the the treatment initiation times, D at times 1500, 1000 and 2000 days. These results reveal that early treatment leads to moderate treatment scheduling. On the other hand, late treatment induces the highest possible dose for long periods, which may lead to premature resistance.

Finally, we studied the performance of the feedback-control based treatment under the instantaneous development of viral resistance to chemotherapy (data not shown). To this end, we assumed a successive 15% sudden change at day 1500 of the parameter \hat{N} ; the number of free virus produced by $T_2(t)$ cells. Although the parameter \hat{N} can not verified from clinical data, the modeling error estimator is able to detect these changes. In this case after a sudden change in \hat{N} , the control feedback has to rectify the steady state value of chemotherapy, which increases as N also increases. These results suggest that the steady state value of the control, say u , can be used to monitor mutations and resistance of the virus to drugs. In this way, large values of u may indicate adaptation of the virus to chemotherapies.

It should be stressed that the numerical results presented above do not imply that the feedback control approach to HIV chemotherapy proposed in this work is a finished methodology. Instead, our objective has shown the strength of using control theory tools within a cross disciplinary framework to attack problems in medicine.




Figure 7: Dynamics of the controlled immune-HIV interaction for different chemotherapy initiation times, D .

Acknowledgements. JXVH acknowledges support from a CONACYT (1998) grant, DEK acknowledges support from NIH grant # R01 HL62119.

References

- [1] Z Agur. A new method for reducing cytotoxicity of the anti-AIDS drug AZT. *Biomedical Modeling and Simulation* ed. D.S. Levine. J. C. Baltzer AG Scientific Publishing Co IMACS, 1:59-61, 1989.
- [2] J. Alvarez-Ramirez, M Meraz, and JX Velasco-Hernandez. A feedback control strategy for the chemotherapy of HIV. *International J. Of Bif. and Chaos (to appear)*, 2000.
- [3] DJ Anderson, TR O'Brien, JA Politch, A Martinez, GR Seage, and et al. Effects of disease stage and azt therapy on the detection of hiv-1 in semen. *JAMA*, 267:2769-2774, 1992.
- [4] RM Anderson and RM May. Complex dynamical behaviour in the interaction between HIV and the immune system. *Cell-to-cell signalling: experiments to theoretical models*, pages 335-349, 1989.
- [5] RW Anderson. How adaptive antibodies facilitate the evolution of natural antibodies. *Immun. Cell Biol.*, 74:286-291, 1996.
- [6] RW Anderson, MS Ascher, and HW Sheppard. Direct HIV cytopathicity cannot account for CD4 decline in AIDS in the presence of homeostasis: A worst-case dynamical analysis. *J. AIDS and Human Retrov.*, 17:245-252, 1998.
- [7] A Asachenkov, G Marchuk, R Mohler, and S. Zuev. *Disease Dynamics*. Birkhauser Boston, Cambridge, MA, 1994.
- [8] F. Barr-Sinoussi and et al. Isolation of a t-cell lymphotropic virus from a patient at risk for the acquired immunodeficiency syndrome (AIDS). *Science*, 220:868-871, 1983.
- [9] MJ Blaser and DE Kirschner. Dynamics of *h. pylori* colonization of the human stomach in relation to the host immune response. *Proc. Nat. Acad. Sci.*, page (accepted), 1999.
- [10] RR Brubaker. Mechanisms of bacterial virulence. *Annu. Rev. Microbiol.*, 39:21-50, 1985.
- [11] FM Burnet. *The clonal selection theory of acquired immunity*. Cambridge University Press, UK, 1959.
- [12] CJ Carpenter, MA Fischl, SM Hammer, MS Hirsch, DM Jacobsen, DA Katzenstein, and et al. Antiretroviral therapy for HIV infection. *JAMA*, 276:146-154, 1996.
- [13] W Cavert, DW Notermans, K Staskus, and et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. *Science*, 276:960-964, 1997.
- [14] TW Chun, L Carruth, D Finzi, X Shen, and et al. Quantification of latent reservoirs and total body viral load in HIV-1 infection. *Nature*, 387:183-187, 1997.
- [15] M. Clerici, JA. Sarin, A. Sanderzofsky, AL. Landay, HA. Kessler, F. Hashemi, CW. Hendrix, SP. Blatt, J. Rusnak, MJ. Dolan, RL. Coffman, PA. Henkart, and Shearer GM. Antigen-stimulated apoptotic T-cell death in HIV infection is selective for CD4+ T cells, modulated by cytokines and effected by lymphotoxin. *AIDS*, 10:603-611, 1996.
- [16] JM Coffin. HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. *Science*, 267:483-489, 1995.
- [17] J Cohen. Shooting for the moon with drugs. *Science*, 273:302, 1996.

- [18] AC Collier, RW Coombs, DA Schoenfeld, RL Bassett, J Timpone, A Baruch, and et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. *N. Engl. J. Med.*, 334:1011–1017, 1996.
- [19] RW Cone, P Gowland, M Opravil, P Grob, B Ledergerber, and et al. Levels of HIV-infected peripheral blood cells remain stable throughout the natural history of HIV infection. *AIDS*, 12.
- [20] LN Cooper. Theory of an immune system retrovirus. *Proc. Natl. Acad. Sci.*, 83:9159–9163, 1986.
- [21] D Covert and D Kirschner. Revisiting the early models of the host-pathogen interactions in hiv infection. *Comments on Theoretical Biology*, page in press, 2000.
- [22] J Dolezal and T Hraba. Application of mathematical model of immunological tolerance to HIV infection. *Folia Biologica*, 34:336–340, 1988.
- [23] MP D'Souza and VA Harden. Chemokines and HIV-1 second receptors: Confluence of two fields generates optimism in AIDS research. *Nature Medicine*, 2:1293–1300, 1996.
- [24] J Embretson, M Zupancic, JL Ribas, RA Burke, P Racz, K Tenner-Racz, and AT Haase. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. *Nature*, 362:359–362, 1993.
- [25] J. Estaquier, . Tanaka, T. Suda, S. Nagata, P. Golstein, and JC Ameisen. Fas-mediated apoptosis of CD4+ and CD8+ T cells from human immunodeficiency virus-infected persons: differential in vitro preventive effect of cytokines and protease antagonists. *Blood*, 87:4959–4966, 1996.
- [26] R Freter. *Human Intestinal Microflora in Health and Disease: (Ch.2) Mechanisms that Control the Microflora in the Large Intestine*. Academic Press, Inc., A, 1983.
- [27] DM Gordon and MA Riley. A theoretical and experimental analysis of bacterial growth in the bladder. *Molecular Microbiology*, 6:555–562, 1992.
- [28] WW Grody, S Fliigel, and F Naeim. Thymus involution in the acquired immunodeficiency syndrome. *Am. J. Clin. Pathol.*, 84:85–95, 1985.
- [29] AT Haase, K Henry, M Zupancic, and et al. Quantitative image analysis of HIV-1 infection in lymphoid tissue. *Science*, 274:985–989, 1996.
- [30] D Ho. Viral counts in HIV infection. *Science*, 272:1124–1125, 1996.
- [31] DD Ho, AU Neumann, AS Perelson, and et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. *Nature*, 373:123–126, 1995.
- [32] SHE Kauffman. Immunity to intracellular bacteria. *Annu. Rev. Immunol*, 11:129–163, 1993.
- [33] D Kirschner. A diffusion model for AIDS in a closed heterosexual population: Estimating rates of infection. *SIAM. J. Appl. Math.*, 56(1):143–166, 1996.
- [34] D Kirschner. Dynamics of co-infection with *M. tuberculosis* and HIV-1. *Theoretical Population Biology*, 55:94–109, 1999.
- [35] D Kirschner and MJ Blaser. The dynamics of *h. pylori* infection of the human stomach. *J Theor. Biol*, 176:281–290, 1995.
- [36] D Kirschner, S Lenhart, and S Serbin. Optimizing chemotherapy of HIV infection: Scheduling, amounts and initiation of treatment. *Journal of Mathematical Biology*, 35:775–792, 1997.
- [37] D Kirschner, R Mehr, and A Perelson. The role of the thymus in pediatric HIV-1 infection. *J. AIDS and Hum. Retrov.*, 18:95–108, 1998.

- [38] D Kirschner and A Perelson. A model for the immune system response to HIV: AZT treatment studies. *Mathematical Population Dynamics*, 1:296–310, 1995.
- [39] D Kirschner and GF Webb. A model for treatment strategy in the chemotherapy of AIDS. *Bulletin of Mathematical Biology*, 58(2):367–390, 1996.
- [40] D. Kirschner and GF Webb. Immunotherapy of HIV-1 infection. *J. Biol. Systems*, 6:71–83, 1997.
- [41] D Kirschner and GF Webb. A mathematical model of combined drug therapy of HIV infection. *Journal of Theoretical Medicine*, 1, 1997.
- [42] D Kirschner and GF Webb. Qualitative differences in HIV chemotherapy between resistance and remission outcomes. *Emerging Infectious Diseases*, 3(3):273–283, 1997.
- [43] D. Kirschner and GF Webb. Understanding drug resistance in the monotherapy treatment of HIV infection. *Bulletin of Mathematical Biology*, 59(4):763–785, 1997.
- [44] A Lafeuillade, C Poggi, N Profizi, and et al. Human immunodeficiency virus type 1 in lymph nodes compared with plasma. *J. Infec. Diseases*, 174:404–407, 1996.
- [45] M Lipsitch and BR Levin. The population dynamics of antimicrobial chemotherapy. *Antimicrobial Agents and Chemotherapy*, 41:363–370, 1997.
- [46] M Lipsitch and BR Levin. Population dynamics of tuberculosis treatment. *Int J Tuberc lung Dis*, 2:187–199, 1998.
- [47] P. Matzinger. Tolerance, danger and the extended family. *Ann. Rev. Immunol*, 12:991–1045, 1994.
- [48] A McLean and Nowak M. Interactions between HIV and other pathogens. *J. Theoret. Biol.*, 155:69–86, 1991.
- [49] A McLean and Nowak M. Competition between AZT sensitive and AZT resistant strains of HIV. *AIDS*, 6:71–79, 1992.
- [50] GX McLeod and SM Hammer. Zidovudine: 5 years later. *Annals of Internal Medicine*, 117:487–501, 1992.
- [51] R Medzhitov and CA Jr Janeway. Innate immunity: impact on the adaptive immune response. *Curr. Opin. Immunol*, 9:4–9, 1997.
- [52] JW Mellors, CR Rinaldo, P Gupta, RM White, JA Todd, and LA Kingsley. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. *Science*, 272:1167–1170, 1996.
- [53] SJ Merrill. AIDS: Background and the dynamics of the decline of immunocompetence. *Theoretical Immunology, Part Two: A. S. Perelson ed.*, pages 59–75, 1987.
- [54] SJ Merrill. Modeling the interaction of HIV with cells of the immune response. *Mathematical and Statistical Approaches to AIDS Epidemiology: C. Castillo-Chavez ed.*, 83:371–385, 1989.
- [55] M.A. Nowak and C.R.M. Bangham. Population dynamics of immune responses to persistent viruses. *Science*, 272:74–79, 1996.
- [56] MA Nowak and RM May. Mathematical biology of HIV infections: Antigenic variation and diversity threshold. *Math. Biosciences*, 106:1–21, 1991.
- [57] MA Nowak and RM May. Coexistence and competition in HIV infection. *J. Theoret. Biol.*, 159:329–342, 1992.
- [58] MA Nowak, RM May, and RM Anderson. The evolutionary dynamics of HIV-1 quasispecies and the development of immunodeficiency disease. *AIDS*, 4:1095–1103, 1990.

- [59] M Nozyce, M Hobberman, S Arpadi, A Wiznia, G Lambert, and et al. A 12-month study of the effects of oral AZT on neurodevelopmental functioning in a cohort of vertically HIV-infected inner-city children. *AIDS*, 8:635–639, 1994.
- [60] G Pantaleo, C Graziosi, JF Demarest, L Butini, M Montroni, CH Fox, and et al. HIV infection is active and progressive in lymphoid during the clinically latent stage of disease. *Nature*, 362:355–358, 1996.
- [61] WE Paul and RA Seder. Lymphocyte responses and cytokines. *Cell*, 76:241–251, 1994.
- [62] E Pennisi and J Cohen. Eradicating HIV from a patient: not just a dream? *Science*, 272:1884, 1996.
- [63] A Perelson, D Kirschner, and R De Boer. The dynamics of HIV infection of CD4+ T-cells. *Journal of Mathematical Biosciences*, 114:81–125, 1993.
- [64] AS Perelson. Modeling the interaction of the immune system with HIV. *Mathematical and Statistical Approaches to AIDS Epidemiology: Lecture Notes in Biomathematics*, 83:350–370, 1989.
- [65] AS Perelson and PW Nelson. Mathematical analysis of HIV-1 dynamics in vivo. *SIAM Review*, 41:3–44, 1998.
- [66] AS Perelson, AU Neumann, M Markowitz, and et al. HIV-1 dynamics in vivo: Virion clearance rate infected cell life span and viral generation time. *Science*, 271:1582–1586, 1996.
- [67] AN Philips, CA Sabin, A Mocroft, and G Janossy. Antiviral therapy. *Nature*, 375:195, 1995.
- [68] M Piatak, MS Saag, Yang LC, SJ Clark, and D Ho. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. *Science*, 259:1749–1754, 1993.
- [69] DD Richman. HIV therapeutics. *Science*, 272:1886–1887, 1996.
- [70] JP Ridge, EJ Fuchs, and P Matzinger. Neonatal tolerance revisited: turning on newborn t cells with dendritic cells. *Science*, 271:1723–1726, 1996.
- [71] MTL Roos, JMA Lange, REY deGoede, and et al. Viral phenotype and immune response in primary HIV-1 infection. *J Infect Dis*, 165:427–432, 1992.
- [72] J Stephenson. New anti-HIV drugs and treatment strategies buoy AIDS researchers. *JAMA*, 275:579–580, 1996.
- [73] PA Volberding and et al. The duration of zidovudine benefit in persons with asymptomatic hiv infection. *JAMA*, 272:437–442, 1994.
- [74] X Wei, SK Ghosh, ME Taylor, VA Johnson, and et al. Viral dynamics in HIV-1 infection. *Nature*, 373:117–122, 1995.
- [75] T Zhu, H Mo, N Wang, DS Nam, Y Cao, and et al. Genotypic and phenotypic characterizations of hiv-1 in patients with primary infection. *Science*, 261:1179–1181, 1993.

